Literature DB >> 17629504

An optimised methodology for the neurobehavioural assessment in rodents.

Elena Moscardo1, Anne Maurin, Roberto Dorigatti, Pascal Champeroux, Serge Richard.   

Abstract

INTRODUCTION: The most widely used test to identify undesired effects of drugs on the central and the peripheral nervous system is the neurobehavioural observation battery adapted from that first described by Irwin in mice. As a neurobehavioural assessment is based on observations; thus, all factors involved need to be controlled and standardised to make the data collected objective, reproducible, reliable and predictive of safety liabilities.
METHODS: An observation battery comprising 58 signs with assigned full details of numerical scores was defined, and a standard design with associated recording, presenting and analysing data system was established. Validation studies were conducted with chlorpromazine, amphetamine, diazepam or clonidine given orally to rats or mice, in order to assess if this methodology could clearly differentiate the profile of effects produced by these compounds. The analysis of data from 80 control rats allowed for the assessment of the normal behaviour in order to characterise the inter-individual, daytime-related variability and the habituation of animals to the procedure.
RESULTS: The reference compounds induced their typical and expected transient effects on neurobehaviour, observed both in the home cage and open-arena, and on body temperature. In particular, amphetamine induced a stimulation of the nervous system activities and marked hyperthermia. Chlorpromazine, diazepam and clonidine induced depressive, anxiolytic or sedative effects associated with hypothermia. The analysis of data collected in control animals allowed for the identification of 6 signs which scored differently from the assigned normality at the first handling occasion due to the characteristic fear reactions to the unknown, and 9 signs at 8 h post-dose due to the animal's habituation to experimental conditions and handling. DISCUSSION: The neurobehavioural changes expected by reference compounds administration were detected. These results confirm that by using this methodology the normal behaviour of the rat and the mouse, the daytime-related variability and the habituation of animals can be characterised, allowing a refined, reliable and reproducible neurobehavioural assessment of test substances in rodents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17629504     DOI: 10.1016/j.vascn.2007.03.007

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  13 in total

Review 1.  Principles of safety pharmacology.

Authors:  M K Pugsley; S Authier; M J Curtis
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

2.  Koumine exhibits anxiolytic properties without inducing adverse neurological effects on functional observation battery, open-field and Vogel conflict tests in rodents.

Authors:  Chao-Jie Chen; Zhi-Feng Zhong; Zhi-Ming Xin; Long-Hui Hong; Yan-Ping Su; Chang-Xi Yu
Journal:  J Nat Med       Date:  2017-01-19       Impact factor: 2.343

3.  Bioavailability, biodistribution, and CNS toxicity of clinical-grade parvovirus H1 after intravenous and intracerebral injection in rats.

Authors:  Karsten Geletneky; Anne-Laure Leoni; Gabriele Pohlmeyer-Esch; Stephanie Loebhard; Barbara Leuchs; Constance Hoefer; Karin Jochims; Michael Dahm; Bernard Huber; Jean Rommelaere; Ottheinz Krebs; Jacek Hajda
Journal:  Comp Med       Date:  2015-02       Impact factor: 0.982

4.  Pathology, organ distribution, and immune response after single and repeated intravenous injection of rats with clinical-grade parvovirus H1.

Authors:  Karsten Geletneky; Anne-Laure Leoni; Gabriele Pohlmeyer-Esch; Stephanie Loebhard; Andrea Baetz; Barbara Leuchs; Mandy Roscher; Constance Hoefer; Karin Jochims; Michael Dahm; Bernard Huber; Jean Rommelaere; Ottheinz Krebs; Jacek Hajda
Journal:  Comp Med       Date:  2015-02       Impact factor: 0.982

5.  Phenotyping Young GluA1 Deficient Mice - A Behavioral Characterization in a Genetic Loss-of-Function Model.

Authors:  Maria Reiber; Helen Stirling; Rolf Sprengel; Peter Gass; Rupert Palme; Heidrun Potschka
Journal:  Front Behav Neurosci       Date:  2022-06-02       Impact factor: 3.617

6.  Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™.

Authors:  Jean G Sathish; Siddhartha Bhatt; Jamie K DaSilva; Declan Flynn; Stephen Jenkinson; Amit S Kalgutkar; Maggie Liu; Balasubramanian Manickam; Jason Pinkstaff; William J Reagan; Norimitsu Shirai; Ahmed M Shoieb; Madhu Sirivelu; Saurabh Vispute; Allison Vitsky; Karen Walters; Todd A Wisialowski; Lawrence W Updyke
Journal:  Int J Toxicol       Date:  2022-05-21       Impact factor: 2.380

7.  Lentiviral delivery of a vesicular glutamate transporter 1 (VGLUT1)-targeting short hairpin RNA vector into the mouse hippocampus impairs cognition.

Authors:  Madeleine V King; Nisha Kurian; Si Qin; Nektaria Papadopoulou; Ben H C Westerink; Thomas I Cremers; Mark P Epping-Jordan; Emmanuel Le Poul; David E Ray; Kevin C F Fone; David A Kendall; Charles A Marsden; Tyson V Sharp
Journal:  Neuropsychopharmacology       Date:  2013-08-28       Impact factor: 7.853

8.  Toxicity and neuropharmacological effects of elenine.

Authors:  Eduardo Navarro; S J Alonso; R Navarro
Journal:  Evid Based Complement Alternat Med       Date:  2011-05-26       Impact factor: 2.629

9.  Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB.

Authors:  Christiane Gerke; Anna Maria Colucci; Carlo Giannelli; Silvia Sanzone; Claudia Giorgina Vitali; Luigi Sollai; Omar Rossi; Laura B Martin; Jochen Auerbach; Vito Di Cioccio; Allan Saul
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

Review 10.  Transgenic models of spinocerebellar ataxia type 10: modeling a repeat expansion disorder.

Authors:  Karen N McFarland; Tetsuo Ashizawa
Journal:  Genes (Basel)       Date:  2012-07-30       Impact factor: 4.141

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.